Sep 23, 2026
This is the free newsletter you subscribed to. Please enjoy!
Sep 22, 2026
A randomized trial in 148 adults aged 70 to 85 found a dose-dependent gain in walking endurance, and no serious side effects were attributed to the treatment
The first mitochondrial transplant into human eyes has now been performed, and the report describing it went up last month without peer review
A just-published Nature Aging study isolates valine as the lever, and the benefit splits sharply by sex
New research says this five-part measure predicts memory trouble years before it shows up
It is a real scientific first. It is also an 18-person safety study in eye disease, with no placebo and no results expected before 2027.
Sep 15, 2026
Twenty-four randomized trials say they do reduce pain and improve function. The same analysis says nobody can yet tell you which version to buy.
A Harvard team just tracked 147,000 people for up to 30 years, and the payoff from strength training flattens out far earlier than the gym culture suggests.
The FDA cleared it in late August. A separate study says the same protein can flag risk ten years ahead. Those two facts are not the same thing.
The world's first Phase III trial of a machine-discovered drug began dosing this week, three days after the aging data landed
A study of 139 men aged 20 to 93 found the famous energy decline of aging was mostly inactivity in disguise, and pinpointed the one defect exercise could not touch
Sep 8, 2026
Japanese researchers just mapped the T cells of people who reached 110, and the dominant clones carry the same receptor fingerprints as cells found inside lung tumors
In a UCLA randomized trial published in The Lancet Healthy Longevity, older adults who got talk therapy for insomnia avoided the accelerated aging seen in those who only got sleep education, and no pills were involved.
Voyager Therapeutics presented data at the Alzheimer's Association International Conference in London showing that one injection of its gene therapy VY-1706 reduced the protein most responsible for Alzheimer's cognitive decline by up to 75% across key brain regions, with no adverse effects at any dose tested.
A new Nature Communications study from Revel Pharmaceuticals and Calico Life Sciences describes CMLase, an enzyme that removes a chemical aging mark from long-lived proteins, reducing it in elderly human skin to levels found in 31-year-olds.
A study published in Cell Death and Disease on July 10, 2026, shows that a single enzyme called acid ceramidase is the hidden link between two of the most destructive forces in aging cells, and removing it protects both old and young cells from collapse
Sep 1, 2026
A new Nature Medicine review by Eric Topol and Tony Wyss-Coray finds that when your brain and immune system age at a normal pace, your survival over the next 15 to 17 years approaches 100%, even if other organs are aging fast.
Two studies published in Nature this March analyzing data from more than 31,000 people found that a smaller thymus predicts a higher risk of death, cancer, and heart failure, and now biotech companies are racing to grow it back.
A new study in Blood found that healing the bone marrow's support environment, rather than the stem cells themselves, dramatically accelerates blood cell recovery after chemotherapy and radiation, and a single small molecule makes it happen.
A new review in the European Journal of Pharmacology found that SGLT2 inhibitors, a widely prescribed class of diabetes drugs, activate the same cellular longevity pathways triggered by fasting, caloric restriction, and senolytics, benefits that have nothing to do with blood sugar.
A large Harvard-led randomized trial found that taking a daily multivitamin for two years slowed biological aging by the equivalent of about four months, with the biggest gains going to people who were already aging faster than their chronological age.
Aug 25, 2026
A new PNAS study screened 400 genetic switches and found that flipping just one EZH2 rejuvenated aged mouse livers as effectively as the full Yamanaka cocktail scientists have relied on for years.
A new Oxford researcher tears apart the data behind longevity hotspots, while a second book asks a more urgent question: regardless of the science, how do you actually live well after 50?
Eli Lilly just published Phase 1 data on a gene-editing therapy that permanently silences the cholesterol gene in your liver, and the results in 35 people are turning heads at the highest levels of cardiology.
An immune-activating drug called Anktiva is producing results in the deadliest brain cancer that researchers are calling nearly unprecedented, and it's not even approved for this disease yet.
